Selected References
- Alsebayel MM, et al. 2018. Congenital esophageal atresia and microtia in a newborn secondary to mycophenolate mofeil exposure during pregnancy: A case report and review of the literature. Am J Case Rep 3(19) 523-526.
- Coscia LA, et al. 2015. Update on the teratogenicity of maternal mycophenolate mofetil. J Pediatr Genet 4(2):42-55.
- Hoeltzenbein M, et al. 2012. Teratogenicity of mycophenolate confirmed in a prospective study of the European Network of Teratology Information Services. Am J Med Genet A 158A(3):588-596.
- Jones A, et al. 2013. Outcomes of pregnancies fathered by solid-organ transplant recipients exposed to mycophenolic acid products. 23(2)153-157.
- Kim M, Rostas S, and Gabardi S. 2013. Mycophenolate fetal toxicity and risk evaluation and mitigation strategies. Am J Transplant 13(6):1383-1389.
- King RW, et al. 2017. Pregnancyoutcomes related to mycophenolate exposure in female kidney transplant recipients. Am J Transplant 17(1)151-160.
- Martin MC et al. 2014. Esophageal atresia and prenatal exposure to mycophenolate. Reprod Toxicol 50:117-121, 2014.
- Midtvedt K, et al. 2017. Exposure to mycophenolate and fatherhood. Transplantation 101(7) e214-217.
- Perez-Aytes A, et al. 2017. Mycophenolate mofetil embryopathy: A newly recognized teratogenic syndrome. Eur J Med Genet 60(1):16-21.
- Sifontis NM, et al. 2006. Pregnancy outcomes in solid organ transplant recipients with exposure to mycophenolate mofetil or sirolimus. Transplantation 82:1698-1702.
